Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation - PubMed (original) (raw)
. 2012 May 7;209(5):903-11.
doi: 10.1084/jem.20112408. Epub 2012 Apr 30.
Carles Ubeda, Ying Taur, Clarissa C Menezes, Raya Khanin, Jarrod A Dudakov, Chen Liu, Mallory L West, Natalie V Singer, Michele J Equinda, Asia Gobourne, Lauren Lipuma, Lauren F Young, Odette M Smith, Arnab Ghosh, Alan M Hanash, Jenna D Goldberg, Kazutoshi Aoyama, Bruce R Blazar, Eric G Pamer, Marcel R M van den Brink
Affiliations
- PMID: 22547653
- PMCID: PMC3348096
- DOI: 10.1084/jem.20112408
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation
Robert R Jenq et al. J Exp Med. 2012.
Abstract
Despite a growing understanding of the link between intestinal inflammation and resident gut microbes, longitudinal studies of human flora before initial onset of intestinal inflammation have not been reported. Here, we demonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflammation secondary to graft-versus-host disease (GVHD) is associated with major shifts in the composition of the intestinal microbiota. The microbiota, in turn, can modulate the severity of intestinal inflammation. In mouse models of GVHD, we observed loss of overall diversity and expansion of Lactobacillales and loss of Clostridiales. Eliminating Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas reintroducing the predominant species of Lactobacillus mediated significant protection against GVHD. We then characterized gut flora of patients during onset of intestinal inflammation caused by GVHD and found patterns mirroring those in mice. We also identified increased microbial chaos early after allogeneic BMT as a potential risk factor for subsequent GVHD. Together, these data demonstrate regulation of flora by intestinal inflammation and suggest that flora manipulation may reduce intestinal inflammation and improve outcomes for allogeneic BMT recipients.
Figures
Figure 1.
GVHD in mice produces marked changes in the microbiota. (A) B6 mice were lethally irradiated and transplanted with 5 × 106 B10.BR T cell–depleted BM supplemented with or without 1 × 106 splenic T cells. Features of GVHD are indicated on ileal histology sections from day 14, including lymphocytic infiltration (block arrows), crypt regeneration (enlarged crypts and hyperchromasia), and apoptosis (black arrows). Paneth cells are indicated (blue arrows). Bar, 20 µm. Representative images are shown from one of two independent experiments with similar results. Each dot represents an individual mouse, with bars indicating medians. (B) Quantitation of bacterial load of ileal contents on day 14 was performed by quantitative PCR of 16S rRNA gene copies. Results of a single experiment are shown. (C) Quantification of IgA levels in ileal contents on day 14 was performed by ELISA. Results of a single experiment are shown. (D) Comparison of representation by Unclassified Firmicutes, Barnesiella, and unclassified Porphyromonadaceae from ileal samples. Combined results from three experiments are shown. (E) Diversity of ileal floras from mice with GVHD was determined by the Shannon index. Combined results from two experiments are shown. (F) Principal coordinate analysis of unweighted UniFrac, of ileal floras from B6 mice transplanted with syngeneic (syn) or allogenic (allo) BM with or without T cells. Combined results from three experiments, with data points from each experiment indicated by number. Mice from experiment three were housed individually. (G) Dissimilarity of ileal floras of allo BMT recipient mice without and with GVHD compared with untreated mice by Bray-Curtis index. Combined results of two (Day 7) and 3 (Day 14) experiments are shown.
Figure 2.
GVHD in mice produces marked changes in the microbiota. (A) B6 mice were transplanted with B10.BR donor BM and T cells as in Fig. 1. Comparison of representation by Lactobacillales, Clostridiales, and other Firmicutes from ileal samples. Combined results from three experiments are shown. (B) Comparison of representation by Lactobacillales, Clostridiales, and other Firmicutes from cecal samples. Combined results from two experiments are shown. (C) Bacterial composition at the genus level of ileal flora on day 14 after BMT are depicted with individual mice displayed in each bar. Results of three separate experiments, each displayed in a row, are shown. Additional untransplanted mice were treated with osmotic laxative or DSS starting on day 7 and also individually housed. (D) Mice were transplanted using the strain combinations indicated; mouse vendor was The Jackson Laboratory unless otherwise indicated. Bar graphs show bacterial composition of ileal contents at the genus level for individual mice on day 14.
Figure 3.
Composition of intestinal flora can impact on severity of intestinal GVHD. (A) Schematic of treatment: B6 mice received ampicillin for 1 wk, followed by a 2-wk recovery period with unmodified drinking water; some were gavaged every 2 d with L. johnsonii (Lacto) of B6 flora origin during recovery, followed by harvest or BMT. Ileal contents were evaluated on days 0 (no BMT) and 14 after BMT. Bar graphs show bacterial composition of ileal contents at the genus level for individual mice. (B) Similar to as in A, BM12 mice received ampicillin followed by recovery; some also received L. johnsonii reintroduction. GVHD was induced upon transplantation with BM and either wild-type CD4 T cells (500K) or ABM RAG1 KO TCR transgenic CD4 T cells (100K). (C) B6 mice were treated with ampicillin, and then were or were not gavaged with L. johnsonii and transplanted with B10.BR BM and T cells. (top) Survival data combined from two experiments with similar results. (bottom) Pathological scores of GVHD target organs on day +21.
Figure 4.
GVHD produces marked changes in the microbiota of humans, and the microbiota may affect risk of developing GVHD. (A) Summary of clinical parameters of non-GVHD and GVHD patients. (B) Flora diversity, by Shannon index, of stool samples after BMT. Individual measurements of diversity are displayed, as well as moving averages and P values calculated for 10-d intervals. (C) Contribution of bacterial populations in samples during two time periods, days 0 to 13 and 14 to 21 after BMT. (D) Microbial chaos of stool samples by mean Bray-Curtis time index from pre-BMT to day 13 after BMT.
Comment in
- Transplant immunology: Gut bugs and grafts.
Bird L. Bird L. Nat Rev Immunol. 2012 May 25;12(6):399. doi: 10.1038/nri3236. Nat Rev Immunol. 2012. PMID: 22627853 No abstract available. - From infection to colonization: the role of microbiota in transplantation.
Upadhyay V, Fu YX, Bromberg JS. Upadhyay V, et al. Am J Transplant. 2013 Apr;13(4):829. doi: 10.1111/ajt.12232. Am J Transplant. 2013. PMID: 23551627 Free PMC article. No abstract available.
Similar articles
- Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.
Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, Zhu W, Sporrer D, Hehlgans T, Kreutz M, Holler B, Wolff D, Edinger M, Andreesen R, Levine JE, Ferrara JL, Gessner A, Spang R, Oefner PJ. Holler E, et al. Biol Blood Marrow Transplant. 2014 May;20(5):640-5. doi: 10.1016/j.bbmt.2014.01.030. Epub 2014 Jan 31. Biol Blood Marrow Transplant. 2014. PMID: 24492144 Free PMC article. - Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.
Shankar G, Bryson JS, Jennings CD, Morris PE, Cohen DA. Shankar G, et al. Am J Respir Cell Mol Biol. 1998 Feb;18(2):235-42. doi: 10.1165/ajrcmb.18.2.2988. Am J Respir Cell Mol Biol. 1998. PMID: 9476911 - Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR. Lu SX, et al. PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6. PLoS One. 2011. PMID: 21760897 Free PMC article. - The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation.
Murphy WJ, Longo DL. Murphy WJ, et al. Immunol Rev. 1997 Jun;157:167-76. doi: 10.1111/j.1600-065x.1997.tb00981.x. Immunol Rev. 1997. PMID: 9255629 Review.
Cited by
- Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian BA, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew IJ, Proietti M, Grimbacher B, Bulashevska A, Bhatt AS, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar BR, Boerries M, Ayuk F, Zeiser R. Norona J, et al. Blood. 2020 Sep 17;136(12):1442-1455. doi: 10.1182/blood.2020005957. Blood. 2020. PMID: 32542357 Free PMC article. - The microbiome-the revealing of a long time unbeknownst factor for outcome in murine models of graft-versus-host disease.
Kumari R, Palaniyandi S, Hildebrandt GC. Kumari R, et al. Bone Marrow Transplant. 2021 Aug;56(8):1777-1783. doi: 10.1038/s41409-021-01325-7. Epub 2021 May 29. Bone Marrow Transplant. 2021. PMID: 34052837 Review. No abstract available. - Bacterial sepsis and GI tract GVHD: more commensal than you think.
Serody J. Serody J. Blood. 2012 Jul 5;120(1):6-7. doi: 10.1182/blood-2012-05-427435. Blood. 2012. PMID: 22767576 Free PMC article. - Accounting for reciprocal host-microbiome interactions in experimental science.
Stappenbeck TS, Virgin HW. Stappenbeck TS, et al. Nature. 2016 Jun 9;534(7606):191-9. doi: 10.1038/nature18285. Nature. 2016. PMID: 27279212 - Alteration in the Skin Microbiome in Cutaneous Graft Versus Host Disease.
Gu Y, Sun J, Li K, Wu X, Zhang J. Gu Y, et al. Acta Derm Venereol. 2021 Jan 20;101(1):adv00374. doi: 10.2340/00015555-3613. Acta Derm Venereol. 2021. PMID: 32812057 Free PMC article.
References
- Beelen D.W., Elmaagacli A., Müller K.D., Hirche H., Schaefer U.W. 1999. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood. 93:3267–3275 - PubMed
- Blazar B.R., Taylor P.A., Boyer M.W., Panoskaltsis-Mortari A., Allison J.P., Vallera D.A. 1997. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J. Immunol. 159:3460–3473 - PubMed
- Blazar B.R., Lees C.J., Martin P.J., Noelle R.J., Kwon B., Murphy W., Taylor P.A. 2000. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J. Immunol. 165:4901–4909 - PubMed
- Cooke K.R., Kobzik L., Martin T.R., Brewer J., Delmonte J., Jr, Crawford J.M., Ferrara J.L. 1996. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 88:3230–3239 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL069929/HL/NHLBI NIH HHS/United States
- P01 CA023766/CA/NCI NIH HHS/United States
- R01-AI34495/AI/NIAID NIH HHS/United States
- R01 AI034495/AI/NIAID NIH HHS/United States
- R01-HL069929/HL/NHLBI NIH HHS/United States
- R01-AI042135/AI/NIAID NIH HHS/United States
- R01-CA107096/CA/NCI NIH HHS/United States
- R01 HL056067/HL/NHLBI NIH HHS/United States
- R01 AI042135/AI/NIAID NIH HHS/United States
- P01 CA142106/CA/NCI NIH HHS/United States
- P01-CA023766/CA/NCI NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- P01 AI056299/AI/NIAID NIH HHS/United States
- R01 CA107096/CA/NCI NIH HHS/United States
- K23 AI095398/AI/NIAID NIH HHS/United States
- R01 AI080455/AI/NIAID NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- R01-HL56067/HL/NHLBI NIH HHS/United States
- R01 AI100288/AI/NIAID NIH HHS/United States
- R37 AI039031/AI/NIAID NIH HHS/United States
- R01-AI080455/AI/NIAID NIH HHS/United States
- R37-AI039031/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases